Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 1994
Business Overview: The Company develops, manufactures, and markets healthcare products (contact lenses, ophthalmic pharmaceuticals, surgical instruments) and provides healthcare services through psychiatric facilities.
Key Financial Metrics
| Metric (in thousands) | Q1 1994 | Q1 1993 |
|---|---|---|
| Net Operating Revenue | $22,907 | $22,360 |
| Net Loss | $(5,150) | $(1,760) |
| Net Loss per Common Share | $(0.17) | $(0.06) |
| Cash and Cash Equivalents (End of Period) | $5,861 | $30,537 |
| Net Cash Used by Operating Activities | $(3,375) | $(14,408) |
| Total Debt (Current + Long-term) | $49,224 | $53,926 |
| Stockholders' Equity (Deficit) | $(4,727) | $452 |
Note: Total Debt calculated as sum of current installments of long-term debt and long-term debt sections.
Material Changes vs. Prior Period
- Revenue: Net operating revenue increased 2.4% to $22.9 million. Product sales rose 20% (driven by CooperVision), while service revenue declined 11% due to managed care pressures.
- Profitability: Net loss widened significantly to $5.15 million from $1.76 million. This was driven by a $1.95 million charge for "Settlement of Disputes" and $429,000 in debt restructuring costs, alongside a $472,000 loss on temporary investments.
- Liquidity: Cash and cash equivalents decreased by $4.25 million to $5.86 million. The decline was primarily due to $5.04 million in payments related to the Exchange Offer and Consent Solicitation.
- Capital Structure: The Company moved from positive equity ($452k) to a deficit position ($4.7M) due to the quarter's losses.
Guidance, Outlook, and Risks
Debt Restructuring
On January 6, 1994, the Company completed an Exchange Offer, issuing $22 million in new 10% Senior Subordinated Secured Notes due 2003 to exchange for approximately $30 million of existing Debentures. This transaction reduced total indebtedness and future interest expense but lowered the conversion price of remaining Debentures to $5.00.
Liquidity and Going Concern
Management anticipates continued net cash outflows in fiscal 1994 due to legal costs, R&D expenses, and potential penalties. The Company explicitly states it needs to raise funds through borrowings, asset sales, or other financings. The independent auditors' report for the prior fiscal year raised "substantial doubt" about the Company's ability to continue as a going concern due to losses, negative cash flows, and contingent liabilities.
Legal Proceedings
Criminal Conviction: The Company was found guilty on six counts of mail fraud and one count of wire fraud related to a "trading scheme" by former Co-Chairman Gary Singer. Sentencing is scheduled for April 1994. Penalties could include fines up to $500,000 per count or twice the gross gain/loss, plus restitution.
SEC Action: The SEC has filed a civil complaint alleging securities law violations. The Company is in settlement negotiations, but no assurance of success exists.
Other Litigation: Pending shareholder derivative actions and patent infringement suits regarding intraocular lenses.
Investor Verification Checklist
- Going Concern Status: Verify the Company's ability to secure additional financing or raise cash to cover operating losses and legal penalties.
- Legal Penalties: Monitor the sentencing outcome in late April 1994 and the status of SEC settlement negotiations to quantify potential financial impact.
- Cash Burn Rate: Assess the sustainability of current cash levels ($5.86M) against projected outflows for legal fees and R&D.
- Debt Covenants: Review the new terms of the 10% Notes and remaining Debentures to ensure compliance with amended covenants.
- Asset Sales: Track progress on planned asset sales (e.g., temporary investments, land, licensing rights) intended to raise liquidity.